home

Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study

R&DPharmacodia.com2015-10-15 00:00 Read   731

Oct. 14, 2015, Eli Lilly and Company and Incyte Corporation announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.

OncoArendi Therapeutics Announces Selection of Its First Clinical Development Candidate for the Treatment of Asthma

R&DPharmacodia.com2015-10-15 00:00 Read   275

October 13, 2015 I On October 13, 2015, OncoArendi Therapeutics Ltd. announced that it selected OATD-01 as its clinical development candidate for the treatment of asthma.

DBV Technologies Announces First Patient Enrolled in Phase II Study of Viaskin Milk

R&DPharmacodia.com2015-10-15 00:00 Read   317

DBV Technologies announced that it has begun enrolling cow's milk-allergic subjects in the Part B (Phase II) of the MILES Phase I/II study (Viaskin MILk Efficacy and Safety).

Vitamin D, calcium do not reduce risk for colorectal adenomas

FrontierPharmacodia.com2015-10-15 00:00 Read   308

Daily supplementation with vitamin D, calcium or both did not significantly decrease risk for recurrent colorectal adenomas, according to the results of a randomized, double blind, placebo-controlled trial.

Johnson & Johnson Innovation Announces Collaborations with Canadian Biotechs Novera Therapeutics, Inc. and enGene, Inc.

TrendPharmacodia.com2015-10-15 00:00 Read   924

October 14, 2015, Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced collaborations with two Canadian biotechnology companies, Toronto-based Novera Therapeutics, Inc. and Montreal-based enGene, Inc.

UCL and Takeda Announce a New Research Partnership to Identify Novel Therapeutic Targets for Neurodegenerative Diseases

TrendPharmacodia.com2015-10-15 00:00 Read   373

October 14, 2015, UCL (University College London) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced a new research collaboration to identify and validate novel target genes for the treatment of neurodegenerative disease.

Ajinomoto Althea, Inc. Expands Manufacturing Capabilities to Antibody Drug Conjugate (ADC) Fill Finish and Bioconjugation

TrendPharmacodia.com2015-10-15 00:00 Read   531

Ajinomoto Althea, Inc. (“Althea”), a leading provider of biopharmaceutical contract development and manufacturing services, today announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates.

Dermira Completes Patient Enrollment for First CIMZIA(R) (Certolizumab Pegol) Phase 3 Clinical Trial in Psoriasis Program

R&DPharmacodia.com2015-10-14 00:00 Read   380

 October 12, 2015, Dermira, Inc. (DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the completion of patient enrollment for the global CIMPASI-2 clinical trial of CIMZIA(R) (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis.

Alder BioPharmaceuticals Initiates Pivotal Clinical Trial of ALD403 for Preventative Treatment of Frequent Episodic Migraine

R&DPharmacodia.com2015-10-14 00:00 Read   370

October 13, 2015, Alder BioPharmaceuticals, Inc. (“Alder”) (ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, Cushing’s disease

Company Releases Financial Releases Product Releases Archived Releases2015201420132012201120102009200820072006 Media Inquiries Fact Sheets Email Alerts Significant Improvements in Skeletal Mineralization and Physical Function Observed in Children with Hypophosphatasia (HPP) Treated With Strensiq™ (asfotase alfa) Sustained for at least Five Years

R&DPharmacodia.com2015-10-14 00:00 Read   524

October 12, 2015, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented new data from the extension phase of an ongoing, open-label Phase 2 study in children with hypophosphatasia (HPP) who were treated with Strensiq™ (asfotase alfa) for at least five years.

Zosano Pharma Announces Positive Phase 2 Results for Its ZP-Glucagon Patch Program for Treatment of Severe Hypoglycemia

R&DPharmacodia.com2015-10-14 00:00 Read   435

October 13, 2015, Zosano Pharma Corporation (ZSAN), a clinical-stage specialty pharmaceutical company, today announced positive results from the Phase 2 clinical trial of its proprietary, rapid onset, transdermal ZP-Glucagon patch for severe hypoglycemia.

Intec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms

R&DPharmacodia.com2015-10-14 00:00 Read   317

Intec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms